Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05390632

Enrollment

100

Registered

2022-05-25

Start date

2019-10-15

Completion date

2023-12-15

Last updated

2023-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PET/MRI

Keywords

Positron-Emission Tomography, lymphoma

Brief summary

Investigating the performance of 18F-FDG PET/CT and PET/MRI in lymphomas

Detailed description

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by 18F-FDG PET (PET/CT and PET/MR). Prior to treatment, all patients will undergo whole-body 18F-FDG PET/CT and PET/MR. The methods' efficiency was compared in the diagnosis of lymph node (LN) and organ involvement.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 80 Years

Healthy volunteers

Inclusion criteria

* pathologically diagnosed as lymphoma; Written informed consent for receiving PET/MRI after PET/CT examinations. cancer planned chemotherapy or immunotherapy scheme. expected survival ≥ 12 weeks

Exclusion criteria

* cannot lie supine for half an hour; refuse to join the clinical researcher; severe liver or kidney dysfunction pregnancy or lactation

Design outcomes

Primary

Measure	Time frame	Description
SUVmax	150 days	Standardized uptake value of 18F-FDG PET/CT and PET/MRI for target lesion of subject or suspected tumor in each time point window (SUV)

Countries

China

Contacts

Primary ContactXuejuan Wang, MD

xuejuan_wang@hotmail.com86 010 88196363

Backup ContactZhi Yang, PhD

Outcome results